Transfer Learning with EfficientNet for Accurate Leukemia Cell Classification

Faisal Ahmed

REVIEW 3 major objections 3 minor 1 cited by

Transfer Learning with EfficientNet for Accurate Leukemia Cell Classification

T0 review · 3 major / 3 minor · reviewed 2026-08-06 · deepseek-v4-flash

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗

Pith's one-line read The paper claims that transfer learning with data augmentation, using EfficientNet-B3, classifies ALL versus healthy blood cells with 94.30% F1, 92.02% accuracy, and 94.79% AUC, outperforming prior C-NMC Challenge results.

desk verdict Routine EfficientNet benchmark on C-NMC; headline numbers are uninterpretable without the split and selection protocol. read the letter →

arxiv 2508.06535 v1 pith:W7TTYKUK submitted 2025-08-04 eess.IV cs.CVcs.LG

Faisal Ahmed This is my paper

classification eess.IVcs.CVcs.LG

keywords transferlearningEfficientNetleukemiacellclassificationbloodsmearimagedataaugmentationC-NMCChallengeclassimbalance

verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

The paper tests whether pretrained convolutional neural networks, fine-tuned on blood-smear images, can accurately separate acute lymphoblastic leukemia (ALL) from non-leukemic cells. To handle a class imbalance, the authors balance the training set with heavy data augmentation, giving 10,000 images per class. They compare five models—ResNet50, ResNet101, and EfficientNet B0, B1, and B3—and report that EfficientNet-B3 performs best. The central claim is that this combination of augmentation and transfer learning beats previously reported results on the C-NMC Challenge, with an F1-score of 94.30%, accuracy of 92.02%, and AUC of 94.79%. If true, it suggests an off-the-shelf pretrained network with simple balancing can serve as a practical screening tool.

What carries the argument

The central machinery is transfer learning with a pretrained EfficientNet backbone, whose compound scaling jointly widens depth, width, and input resolution; the B3 variant is the version that best fits this dataset's size. The other key component is data augmentation, which turns an imbalanced real-world set into a balanced 10,000-per-class training set. The evaluation compares five architectures and selects the best by F1-score.

What would settle it

Run the same five architectures on the C-NMC Challenge data using a strict patient-disjoint split with augmentation applied only after splitting, and check whether EfficientNet-B3 still reaches 94.30% F1; if its score drops materially, the published numbers were inflated by data leakage or test-set reuse.

Watch

Extended reading notes

Core claim

On the paper's own terms, the discovery is that compound-scaled EfficientNet, specifically B3, when fine-tuned from ImageNet weights and trained on an augmented balanced set of 10,000 images per class, separates leukemic from healthy blood cells more accurately than the alternative architectures tested. The authors report it reaching 94.30% F1, 92.02% accuracy, and 94.79% AUC, exceeding previously reported methods on the C-NMC Challenge. They attribute the gain to efficient parameter use through compound scaling and to the reduction of class-imbalance bias through augmentation.

Load-bearing premise

The load-bearing premise is that the test images are genuinely unseen examples from different patients, and that the best-of-five model selection used only training and validation data, not the test set; the abstract does not provide the split details.

Editorial extensions

If this is right

With balanced training, EfficientNet-B3 can be used as a screening classifier for ALL from peripheral blood smears.
The augmentation recipe of 10,000 images per class makes imbalanced cytology data trainable without collecting more slides.
EfficientNet-B3 sets a new reported benchmark on the C-NMC Challenge, beating earlier published scores.
Because the comparison includes ResNet50 and ResNet101, the result also shows that compound-scaled architectures outperform older standard backbones on this task.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

If the reported split is at the image level rather than the patient level, the 94.30% F1-score likely overstates performance when the model meets a new patient, since images from the same patient can appear in both training and test sets.
A stronger test would be a patient-disjoint cross-validation; if the scores drop materially, the headline number would shrink toward the clinical reality.
The same augmentation-and-balance recipe could transfer to other scarce medical image datasets, though the optimal number of augmented images per class likely depends on dataset difficulty.
Beyond leukemia, the result suggests that picking an EfficientNet scale by validation F1, rather than defaulting to the largest network, is a cheap and effective model-selection rule.

Share X Bluesky LinkedIn Reddit HN

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Desk Editor's Note

read the letter

Quick take: this is a routine transfer-learning benchmark on a public leukemia dataset. The one thing worth knowing is that the abstract does not disclose the data split or the model-selection protocol, so the headline F1 of 94.30% cannot be evaluated as a generalization estimate. The balanced augmentation to 10,000 images per class is a sensible, standard fix for class imbalance and is executed cleanly in the description. The paper does not claim a new architecture or training procedure, and the novelty is a performance number on C-NMC Challenge.

The soft spots are exactly where the stress-test note lands. We are told five models were evaluated and EfficientNet-B3 was best, but not whether the test set was held out before that comparison. If the best model was chosen by test-set accuracy across five runs, the reported numbers are optimistic. More importantly, the split level is never stated. If augmentation happened before splitting, or if the split is at the image level rather than patient level, there is likely identity leakage between train and test. That would inflate all metrics, and the comparison to prior C-NMC results becomes apples-to-oranges. No confidence intervals are reported, so we cannot tell whether the margin over prior work is noise.

I want to be clear: none of this is an internal inconsistency. The abstract is just underspecified on the load-bearing details. If the full paper states a patient-level split, separate validation set, and reports CIs on the test metrics, the central claim likely holds up as a modest incremental result. Without that, the numbers are not credible.

Who is this for? A reader looking for a quick baseline for EfficientNet on ALL classification might glance at it. It does not change practice and does not open a new direction. It is the kind of paper that belongs at a workshop or a low-tier applied journal, only if the protocol details are airtight. As it stands, I would not desk-reject it outright; I would send it to a referee with instructions to verify the split and selection protocol. A serious referee can resolve the ambiguity in an hour. That is exactly what the paper needs.

Referee Report

3 major / 3 minor

Summary. The paper proposes a transfer-learning pipeline for classifying Acute Lymphoblastic Leukemia (ALL) from peripheral blood smear images, using the C-NMC Challenge dataset. The authors apply data augmentation to create a balanced training set of 10,000 images per class from 3,631 Hematologic and 7,644 ALL images, and compare ResNet50, ResNet101, and EfficientNet B0/B1/B3. They report that EfficientNet-B3 achieves the best F1-score (94.30%), accuracy (92.02%), and AUC (94.79%), and claim that these results outperform previously reported methods on the C-NMC Challenge.

Significance. If the reported results are reliable, this is a practically useful contribution to an active area of medical image analysis, and the use of a public benchmark dataset allows comparison with prior work. The paper also has a potential strength in its explicit use of transfer learning and augmentation to address class imbalance. However, the current evidence is insufficient to establish the central performance claim, because the evaluation protocol is not described: the abstract does not disclose the data split level (patient vs. image), the augmentation timing relative to the split, the model-selection procedure, or any measure of statistical variability. These omissions are not cosmetic; they determine whether the headline numbers reflect genuine generalization or leakage and selection artifacts.

major comments (3)

[Abstract] The abstract does not state whether the train/test split was performed at the patient level or at the image level, nor whether data augmentation was applied before or after splitting. If augmented copies of the same original image appear in both the training and test sets, the classifier can exploit near-duplicate image features and the reported F1, accuracy, and AUC will be inflated. This is a load-bearing issue for the central claim, and it must be clarified with a precise description of the split and augmentation workflow.
[Abstract] The abstract states that 'several models' were evaluated and that EfficientNet-B3 'achieved the best results,' but it does not mention a separate validation set. If the best-performing model was selected by comparing test-set performance across the five architectures, the reported metrics are optimistic selection artifacts rather than unbiased generalization estimates. The paper must specify how model selection was performed and whether the final evaluation set was held out from all selection decisions.
[Abstract] The reported F1-score, accuracy, and AUC are given as single point estimates with no confidence intervals, standard deviations, or significance tests. Without multiple splits, cross-validation, or bootstrapping, the claim of 'outperforming previously reported methods' is not statistically grounded. The authors should report variability measures and, where possible, a statistical comparison with prior results on the same benchmark.

minor comments (3)

[Abstract] There are typographical errors in the abstract, such as 'andAUCof94.79%,outperformingpreviouslyreported,' which should be corrected to include proper spacing and punctuation.
[Abstract] The abstract does not cite the specific version or exact source of the C-NMC Challenge dataset; a reference should be provided so that readers can identify the exact benchmark and its official train/test split.
[Abstract] The term 'accuracy' is ambiguous in the context of a class-imbalanced dataset; the authors should specify whether this is overall accuracy, balanced accuracy, or another metric, and define all metrics consistently.

Circularity Check

0 steps flagged · score 0.0 of 10

No circularity: the reported results are empirical measurements, not a derivation chain.

full rationale

This abstract-only paper reports an empirical comparison of transfer learning models for leukemia cell classification. There is no mathematical derivation, no equation-level construction, and no parameter that is fitted and then renamed as a prediction. The performance numbers (F1 94.30%, accuracy 92.02%, AUC 94.79%) are presented as measurements from an evaluation protocol, not as consequences of a model defined in terms of those numbers. No self-citation, uniqueness theorem, or ansatz is invoked. The reader's concern about a possible image-level split or model selection on the test set is a threat to statistical validity and external generalization, but it is not circularity: even if the best model was chosen by comparing test-set metrics across five architectures, the reported metric is a selected maximum rather than a quantity that equals its own input by construction. Because no circular step can be identified from the text, the appropriate finding is no significant circularity.

Assumptions & free parameters 3 free parameters · 3 assumptions · 0 invented entities

The central claim rests on several unstated choices: model selection, augmented training size, augmentation details, and an unbiased data split. No new entities are introduced.

free parameters (3)

Model architecture = EfficientNet-B3
The best-performing model was selected from five candidates based on validation performance; this is a model-selection parameter.
Augmented training size per class = 10,000
The number of images per class after augmentation was chosen to balance the dataset; it affects the trained model.
Data augmentation hyperparameters = unspecified
The types, magnitudes, and probabilities of augmentation operations are not described, yet they influence the final result.

assumptions (3)

domain assumption ImageNet-pretrained weights provide a useful starting point for blood cell image classification.
The method assumes transfer learning from natural images helps in this medical domain, a claim not justified in the abstract.
domain assumption The public C-NMC dataset images are representative of clinical leukemia diagnosis.
The study assumes the benchmark data reflects real-world blood smear images, which is not established in the abstract.
domain assumption The train/test split used for the reported metrics is unbiased and patient-disjoint.
The abstract does not describe the split, so the validity of the reported performance depends on this unstated assumption.

how reviews work

0 comments

Cite this review

Pith. "Pith review of Transfer Learning with EfficientNet for Accurate Leukemia Cell Classification." pith.science (2026). https://pith.science/paper/W7TTYKUK

@misc{pith2026250806535,
  author       = {Pith},
  title        = {Pith review of: Transfer Learning with EfficientNet for Accurate Leukemia Cell Classification},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/W7TTYKUK}},
  note         = {Machine review of arXiv:2508.06535}
}

read the original abstract

Accurate classification of Acute Lymphoblastic Leukemia (ALL) from peripheral blood smear images is essential for early diagnosis and effective treatment planning. This study investigates the use of transfer learning with pretrained convolutional neural networks (CNNs) to improve diagnostic performance. To address the class imbalance in the dataset of 3,631 Hematologic and 7,644 ALL images, we applied extensive data augmentation techniques to create a balanced training set of 10,000 images per class. We evaluated several models, including ResNet50, ResNet101, and EfficientNet variants B0, B1, and B3. EfficientNet-B3 achieved the best results, with an F1-score of 94.30%, accuracy of 92.02%, andAUCof94.79%,outperformingpreviouslyreported methods in the C-NMCChallenge. Thesefindings demonstrate the effectiveness of combining data augmentation with advanced transfer learning models, particularly EfficientNet-B3, in developing accurate and robust diagnostic tools for hematologic malignancy detection.

Discussion (0). Sign in to comment.

Forward citations

Cited by 1 Pith paper

Reviewed papers in the Pith corpus that reference this work. Sorted by Pith novelty score. Full citation record

RepViT-CXR: A Channel Replication Strategy for Vision Transformers in Chest X-ray Tuberculosis and Pneumonia Classification
cs.CV 2025-09 reject novelty 2.0 of 10

Applying a standard channel-replication trick to a pretrained Vision Transformer yields very high reported accuracy for TB and pneumonia classification on three chest X-ray datasets.

Pith tools

Reviewed August 6, 2026 · model on record in the stance chip above.